trending Market Intelligence /marketintelligence/en/news-insights/trending/63mC4yLcG8fThLFw5WxwGQ2 content esgSubNav
In This List

SIGA Technologies seeks US FDA approval for smallpox treatment

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


SIGA Technologies seeks US FDA approval for smallpox treatment

SIGA Technologies Inc. submitted a new drug application to the U.S. Food and Drug Administration for its smallpox treatment Tpoxx.

Tpoxx was developed to treat smallpox, as well as other orthopoxvirus infections. There is no cure or treatment approved for smallpox.

SIGA has requested an expedited review of its application. The advanced development of Tpoxx is funded by the U.S. government's Biomedical Advanced Research and Development Authority.

The drug is administered in oral form and was developed under the U.S. FDA's animal rule in which efficacy endpoints are determined in animal studies, and human clinical studies are conducted to determine the safety and confirm dosing.

SIGA expects a response from the U.S. FDA in February 2018.